QY Research Inc. (Global Market Report Research Publisher) announces the release of 2025 latest report “In Vivo Bioluminescence Imaging System- Global Market Share and Ranking, Overall Sales and Demand Forecast 2026-2032”. Based on current situation and impact historical analysis (2020-2024) and forecast calculations (2026-2032), this report provides a comprehensive analysis of the global In Vivo Bioluminescence Imaging System market, including market size, share, demand, industry development status, and forecasts for the next few years.
The global market for In Vivo Bioluminescence Imaging System was estimated to be worth US$ 122 million in 2025 and is projected to reach US$ 186 million, growing at a CAGR of 6.3% from 2026 to 2032.
【Get a free sample PDF of this report (Including Full TOC, List of Tables & Figures, Chart)】
https://www.qyresearch.com/reports/6698889/in-vivo-bioluminescence-imaging-system
In Vivo Bioluminescence Imaging System Market Summary
An in vivo bioluminescence imaging system is a scientific research instrument that utilizes bioluminescent reactions to perform non-invasive imaging of cells, genes, tumors, pathogens, or drug-action processes within living animals. Typically, this is achieved by inoculating experimental animals with cells expressing luciferase—or by creating animal models carrying a luciferase reporter gene—and subsequently injecting a corresponding substrate, such as luciferin; a high-sensitivity CCD or CMOS camera then captures the faint light signals generated in vivo. This system enables the continuous monitoring of disease progression, tumor growth, metastasis, infection dissemination, gene expression, and therapeutic responses without the need to euthanize the animals. It is widely employed in animal-based experimental research across fields such as oncology, immunology, infectious disease studies, drug screening, gene therapy, and regenerative medicine.
According to the new market research report “Global In Vivo Bioluminescence Imaging System Market Report 2026-2032”, published by QYResearch, the global In Vivo Bioluminescence Imaging System market size is projected to reach USD 0.18 billion by 2032, at a CAGR of 6.3% during the forecast period.
Figure00001. In Vivo Bioluminescence Imaging System Industry Chain
Figure00002. Global In Vivo Bioluminescence Imaging System Market Size (US$ Million), 2021-2032
Above data is based on report from QYResearch: Global In Vivo Bioluminescence Imaging System Market Report 2026-2032 (published in 2026). If you need the latest data, plaese contact QYResearch.
Figure00003. Global In Vivo Bioluminescence Imaging System Top 21 Players Ranking and Market Share (Ranking is based on the revenue of 2025, continually updated)
Above data is based on report from QYResearch: Global In Vivo Bioluminescence Imaging System Market Report 2026-2032 (published in 2026). If you need the latest data, plaese contact QYResearch.
According to QYResearch Top Players Research Center, the global key manufacturers of In Vivo Bioluminescence Imaging System include Perkin Elmer, Idexx Laboratories, Aspect Imaging, Fujifilm Visualsonics, Trifoil Imaging, Bruker, Sunny Optical, Photon, Spectral Instruments Imaging, MILABS, etc. In 2025, the global top five players had a share approximately 54.0% in terms of revenue.
Figure00004. In Vivo Bioluminescence Imaging System, Global Market Size, Split by Product Segment
Based on or includes research from QYResearch: Global In Vivo Bioluminescence Imaging System Market Report 2026-2032.
In terms of product type, Optical Imaging is the largest segment, hold a share of 65.5%,
Market Drivers:
1. Growing Demand for New Drug R&D and Preclinical Efficacy Evaluation
The primary driving force behind in vivo bioluminescence imaging systems stems from pharmaceutical R&D—particularly in preclinical studies involving oncology, infectious diseases, immunology, and cell therapies. These systems enable the continuous, in vivo monitoring of tumor growth, pathogen dissemination, cell homing, and therapeutic efficacy within small animals. Compared to traditional methods involving anatomical sampling, this approach offers a more intuitive and dynamic perspective, making it ideally suited for candidate drug screening in pharmaceutical companies, Contract Research Organizations (CROs), and university laboratories. The growth of the preclinical imaging market is also attributed to increased investment in drug development, rising research demands regarding chronic diseases, and the growing need for non-invasive imaging technologies.
2. Research in Oncology and Infectious Disease Models Drives Essential Equipment Demand
Bioluminescence imaging is particularly well-suited for monitoring tumor burden, tracking metastatic lesions, observing bacterial and viral infection models, and evaluating the efficacy of immunotherapies, as the emitted light signals can typically be correlated with cell counts, lesion progression, or gene expression levels. In oncology and infectious disease studies, researchers can perform multiple imaging sessions on the same animal subject to continuously track disease progression, thereby establishing these systems as an essential component of preclinical animal research platforms.
3. Distinct Advantages in Non-Invasive, Longitudinal Dynamic Monitoring
Traditional animal experiments often necessitate the euthanasia of animals at various time points to collect samples; conversely, in vivo bioluminescence imaging allows for repeated observations of the same experimental subject without the need for euthanasia. This approach minimizes inter-individual variability while enhancing data continuity and statistical reliability. Revvity’s IVIS system, for instance, highlights its utility in longitudinal studies of disease progression and therapeutic responses; this capability for “continuous, within-subject monitoring” represents a key differentiator that distinguishes BLI systems from standard ex vivo detection equipment.
4. The “3Rs” Principle and Animal Ethics Requirements Boost Market Acceptance
As ethical standards for animal experimentation continue to rise, research institutions are placing increasing emphasis on reducing the number of animals used, optimizing experimental designs, and minimizing animal suffering. By enabling repeated measurements on the same individual animal across multiple time points, in vivo bioluminescence imaging reduces the need for large experimental cohorts and minimizes the frequency of terminal dissections, thereby aligning with the “3Rs” principle: Replacement, Reduction, and Refinement. This inherent advantage has significantly enhanced the perceived value of integrating these systems into university laboratories, hospital-based animal research centers, and drug evaluation platforms.
5. Maturity of Optical Imaging Reagents and Reporter Gene Technologies
The widespread adoption of BLI systems has been facilitated by the maturity of key enabling technologies, including luciferase reporter genes, bioluminescent substrates, labeled cell lines, and animal models. With the increasingly stable supply of luciferase-labeled tumor cells, pathogen models, transgenic mice, and imaging substrates, the barrier for users to establish experimental systems has been lowered. Industry data also indicates that optical imaging reagents account for a significant share of preclinical imaging-related products—a trend primarily driven by the widespread use of bioluminescence and fluorescence imaging in preclinical research.
Restraint:
1. High Equipment Acquisition Costs Limit Adoption by Small and Medium-Sized Laboratories
In vivo bioluminescence imaging systems are classified as high-end scientific research instruments. A complete system typically comprises a high-sensitivity CCD/CMOS camera, a deep-cooling refrigeration system, a light-tight dark box, an animal anesthesia and temperature control module, a set of optical filters, and specialized analysis software; imported high-end models, in particular, carry a substantial price tag. For general university laboratories, small hospital research groups, and early-stage pharmaceutical companies, the costs associated with purchasing a single unit, maintaining it, and establishing the necessary supporting animal research platform are significant. Consequently, market expansion for these systems tends to be concentrated primarily within key laboratories, pharmaceutical companies, Contract Research Organizations (CROs), and public research platforms.
2. Relatively Narrow Application Scope, Focused Primarily on Preclinical Small Animal Research
Bioluminescence imaging relies primarily on reporter genes, labeled cells, or luminescent substrate systems; as such, it is best suited for experiments involving small animals—such as mice and rats—and is difficult to directly extend to large animals or clinical human imaging applications. Published review articles also note that, despite its high sensitivity, optical imaging faces limitations regarding tissue penetration depth and quantitative capabilities. This results in a market scope that is significantly smaller than that of general-purpose imaging modalities such as CT, MRI, and ultrasound.
3. Limited Tissue Penetration Depth and Spatial Resolution
Bioluminescence signals are subject to absorption and scattering effects within animal tissues; consequently, imaging performance degrades when visualizing deep tissues, regions obscured by bone, or larger animal models. A relevant review published in Nature also highlights that the shortcomings of optical imaging include shallow penetration depth, relatively poor spatial resolution, and limited quantitative accuracy. Therefore, when precise anatomical localization, deep-tissue imaging, or high-resolution structural information is required, users often find it necessary to integrate multimodal imaging systems—such as micro-CT, MRI, or PET/SPECT—to complement their optical imaging data.
4. Quantitative Results Are Highly Susceptible to Experimental Conditions
The intensity of a bioluminescence imaging (BLI) signal is determined not only by the number of target cells or the level of gene expression but is also influenced by a host of other factors, including substrate injection dosage, timing of administration, the animal’s anesthetic state, body temperature, tissue depth, imaging angle, and the selection of the Region of Interest (ROI). Several studies have also pointed out the inherent difficulty in achieving absolute quantification of bioluminescence signals, noting that data are particularly prone to bias when acquired from deep tissues or within complex in vivo environments. Consequently, users must strictly standardize their experimental protocols; failure to do so results in poor data comparability across different experimental batches or between different laboratories. 5. High Dependence on Reagents, Animal Models, and Personnel Expertise
An in vivo bioluminescence imaging system is not a device that can be utilized effectively simply by purchasing the equipment; it also necessitates the use of luciferase-labeled cells, transgenic animal models, luminescent substrates, animal anesthesia systems, and standardized imaging protocols. If a laboratory lacks experience in molecular biology, animal experimentation, and quantitative image analysis, the utilization rate of the equipment may remain relatively low. For manufacturers, this also translates into higher costs associated with pre-sales application validation, post-sales training, and methodological support.
Opportunity:
1. Increased R&D Investment in New Drugs Creates Sustained Procurement Opportunities
The core market opportunity for in vivo bioluminescence imaging systems stems from the growing demand for preclinical efficacy evaluation among pharmaceutical companies, CROs, universities, and hospital-based translational medicine platforms—particularly in the fields of oncology, infectious diseases, immunology, cell therapy, and gene therapy. The preclinical optical imaging market is estimated at approximately $620.7 million in 2024 and is projected to maintain growth from 2025 to 2030; this indicates that optical imaging modalities—such as bioluminescence and fluorescence—remain a critical equipment category within preclinical research.
2. Advantages in Longitudinal Dynamic Monitoring Will Boost Equipment Penetration Rates
In vivo bioluminescence imaging enables the continuous observation of disease progression, cell migration, gene expression, and therapeutic responses within the same living animal. This approach reduces the reliance on terminal dissection experiments while enhancing data continuity and comparability. Revvity’s IVIS system, for instance, highlights its utility in longitudinal workflows for monitoring disease progression and treatment efficacy. Consequently, these systems hold significant potential to displace traditional terminal-endpoint experiments in future preclinical efficacy evaluations and disease model studies.
3. Multimodal Imaging Systems Present Opportunities for Product Upgrades
While standalone bioluminescence imaging systems offer high sensitivity, they possess limited capabilities for precise anatomical localization. As a result, multimodal systems—combining bioluminescence, fluorescence, and X-ray or micro-CT imaging—are emerging as the key direction for product upgrades within the high-end market segment. Revvity’s IVIS Spectrum 2 and SpectrumCT 2 systems have already integrated 2D/3D bioluminescence, fluorescence, and CT reconstruction capabilities onto a single platform, demonstrating a clear shift in customer demand from single-modality imaging toward multiparametric, multimodal, and quantitative analytical solutions.
4. Significant Room Exists for Domestic Substitution and Localized Services
Imported high-end in vivo imaging systems are characterized by high costs, lengthy repair cycles, and rigid vendor lock-in regarding software and consumables; this creates a compelling entry opportunity for domestic manufacturers. Given the vast number of universities, hospitals, pharmaceutical companies, and CROs in China—all of which require both basic and mid-to-high-end dual-modality imaging systems—domestic manufacturers can significantly expand their market share. Success hinges on their ability to enhance the stability and reliability of key components and functions—including CCD/sCMOS detectors, dark-box optical paths, anesthesia and temperature control systems, quantitative analysis software, and after-sales support—thereby leveraging their competitive advantages in cost-effectiveness and rapid service response.
5. The Development of CROs and Shared Animal Facility Platforms Will Drive Centralized Procurement
In vivo bioluminescence imaging systems are not high-frequency, small-scale instruments; rather, they are more commonly found in pharmaceutical R&D centers, Contract Research Organizations (CROs), animal research centers, and university-based shared technology platforms. As pharmaceutical R&D, life science infrastructure, and regional CRO hubs continue to expand across the Asia-Pacific region, the demand for preclinical imaging equipment is expected to rise. Market research further indicates that the Asia-Pacific preclinical imaging market is projected to experience rapid growth, driven primarily by R&D activities in the pharmaceutical and biotechnology sectors, government investment in the life sciences, and the expansion of the CRO industry.
The report provides a detailed analysis of the market size, growth potential, and key trends for each segment. Through detailed analysis, industry players can identify profit opportunities, develop strategies for specific customer segments, and allocate resources effectively.
The In Vivo Bioluminescence Imaging System market is segmented as below:
By Company
Perkin Elmer
Canon Medical Systems
Bruker
Idexx Laboratories
Hallmarq Veterinary Imaging
Huantong Nuclear Magnet
Sunny Optical
Photon
MILABS
IThera Medical
Vieworks
Aspect Imaging
TOMOWAVE
Trifoil Imaging
Clinx
Raylight
Spectral Instruments Imaging
Novel Medical
Tanon
Biolight
PINGSENG Healthcare
Fujifilm Visualsonics
Segment by Type
-20°C Class
-40°C Class
-80°C Class
Below -90°C
Segment by Application
Laboratory
Pet Hospital and Clinic
Each chapter of the report provides detailed information for readers to further understand the In Vivo Bioluminescence Imaging System market:
Chapter 1: Introduces the report scope of the In Vivo Bioluminescence Imaging System report, global total market size (valve, volume and price). This chapter also provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry. (2021-2032)
Chapter 2: Detailed analysis of In Vivo Bioluminescence Imaging System manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc. (2021-2026)
Chapter 3: Provides the analysis of various In Vivo Bioluminescence Imaging System market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments. (2021-2032)
Chapter 4: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.(2021-2032)
Chapter 5: Sales, revenue of In Vivo Bioluminescence Imaging System in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world..(2021-2032)
Chapter 6: Sales, revenue of In Vivo Bioluminescence Imaging System in country level. It provides sigmate data by Type, and by Application for each country/region.(2021-2032)
Chapter 7: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc. (2021-2026)
Chapter 8: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 9: Conclusion.
Benefits of purchasing QYResearch report:
Competitive Analysis: QYResearch provides in-depth In Vivo Bioluminescence Imaging System competitive analysis, including information on key company profiles, new entrants, acquisitions, mergers, large market shear, opportunities, and challenges. These analyses provide clients with a comprehensive understanding of market conditions and competitive dynamics, enabling them to develop effective market strategies and maintain their competitive edge.
Industry Analysis: QYResearch provides In Vivo Bioluminescence Imaging System comprehensive industry data and trend analysis, including raw material analysis, market application analysis, product type analysis, market demand analysis, market supply analysis, downstream market analysis, and supply chain analysis.
and trend analysis. These analyses help clients understand the direction of industry development and make informed business decisions.
Market Size: QYResearch provides In Vivo Bioluminescence Imaging System market size analysis, including capacity, production, sales, production value, price, cost, and profit analysis. This data helps clients understand market size and development potential, and is an important reference for business development.
Other relevant reports of QYResearch:
Global In Vivo Bioluminescence Imaging System Market Research Report 2026
Global In Vivo Bioluminescence Imaging System Market Outlook, In‑Depth Analysis & Forecast to 2032
Global In Vivo Bioluminescence Imaging System Sales Market Report, Competitive Analysis and Regional Opportunities 2026-2032
About Us：
QYResearch founded in California, USA in 2007, which is a leading global market research and consulting company. Our primary business include market research reports, custom reports, commissioned research, IPO consultancy, business plans, etc. With over 19 years of experience and a dedicated research team, we are well placed to provide useful information and data for your business, and we have established offices in 7 countries (include United States, Germany, Switzerland, Japan, Korea, China and India) and business partners in over 30 countries. We have provided industrial information services to more than 60,000 companies in over the world.
Contact Us:
If you have any queries regarding this report or if you would like further information, please contact us:
QY Research Inc.
Add: 17890 Castleton Street Suite 369 City of Industry CA 91748 United States
EN: https://www.qyresearch.com
Email: global@qyresearch.com
Tel: 001-626-842-1666(US)
JP: https://www.qyresearch.co.jp
